Ross G. Clark
Keine laufenden Positionen mehr
Karriereverlauf von Ross G. Clark
Ehemalige bekannte Positionen von Ross G. Clark
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Direktor/Vorstandsmitglied | 01.12.2001 | 21.06.2008 |
| Technik-/Wissenschafts-/F&E-Leiter | 01.12.2001 | 21.06.2008 | |
| Auckland University | Corporate Officer/Principal | 01.09.1997 | 21.06.2008 |
| NeuronZ Ltd. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.1997 | 01.01.2000 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1990 | 01.01.1997 |
| ViaLactia Biosciences (NZ) Ltd. | Direktor/Vorstandsmitglied | 01.07.1999 | - |
| Tercica Ltd. | Corporate Officer/Principal | 01.09.2000 | - |
Ausbildung von Ross G. Clark
| Massey University | Doctorate Degree |
Statistik
International
| Neuseeland | 6 |
| Vereinigte Staaten | 3 |
Operativ
| Chief Tech/Sci/R&D Officer | 3 |
| Director/Board Member | 2 |
| Corporate Officer/Principal | 2 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
| Tercica Ltd. | |
| NeuronZ Ltd. | |
| ViaLactia Biosciences (NZ) Ltd. | |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
- Börse
- Insiders
- Ross G. Clark
- Erfahrung
